Table 2.

Overall survival in patients without known node-positive disease (n=3,655).

Cohort	Patients	2-year OS (%)	95% CI	3-year OS (%)	95% CI	4-year OS (%)	95% CI	5-Year OS (%)	95% CI
T1 LVI−	1,065	92.5	90.8–94.2	86.5	84.0–89.0	80.4	77.3–83.7	74.8	70.9–79.0
T1 LVI+	105	83.5	76.4–91.3	77.4	69.0–87.0	73.9	64.7–84.4	64.8	52.8–79.5
T2 LVI−	349	89.3	85.8–92.9	79.4	74.3–84.9	70.3	63.9–77.4	58.9	50.9–68.1
T2 LVI+	102	76.4	68.0–85.9	59.9	49.7–72.1	52.2	41.5–65.7	44.4	33.1–59.6
T3 LVI−	989	76.9	74.1–79.8	67.4	64.1–70.9	60.9	57.2–64.9	52.6	48.2–57.4
T3 LVI+	768	56.7	53.1–60.6	48.3	44.4–52.5	40.7	36.5–45.3	34.7	30.1–40.0
T4 LVI−	72	35.4	25.2–49.7	30.5	20.5–45.4	26.5	16.3–43.0	26.5	16.3–43.0
T4 LVI+	205	25.5	19.9–32.7	16.6	11.7–23.5	12.6	8.0–19.7	9.1	4.8–17.3

OS = overall survival. CI = confidence interval. LVI = lymphovascular invasion. Pathologic T categorization is used.